Dr. Reddy's Laboratories Limited

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Dr. Reddy's Laboratories Limited sits in the top decile of US sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count).

52 total trials none currently recruiting 51 completed early-phase tilt top decile by trial count

Dr. Reddy's Laboratories Limited: 52 sponsored US clinical trials, none currently recruiting.

Dr. Reddy's Laboratories Limited sponsors 52 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 51 completed. 10 of these trials are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 6 trials.

Top-decile sponsor footprint

Dr. Reddy's Laboratories Limited ranks in the top decile of sponsors by registered trial count (#363 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

B 85/100

51 of 52 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (98.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

52 total, page 1 of 2

COMPLETED Phase 3

A Phase III Transition Study of DRL Rituximab to Reference Medicinal Products

NCT04268771

COMPLETED Phase 3

Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

NCT03976102

COMPLETED Phase 2

Efficacy, Tolerability, Safety, and Pharmacokinetic Study of DFN-15

NCT03554772

COMPLETED Phase 2

A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)

NCT03421197

COMPLETED Phase 2

A Bioavailability Study of DFD-03 Compared to Tazorac® in Patients With Moderate Acne Vulgaris

NCT03599193

COMPLETED Phase 2

A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris

NCT03341910

COMPLETED Phase 3

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

NCT03290027

COMPLETED Phase 3

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

NCT03292640

COMPLETED Phase 1

Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects

NCT03282838

COMPLETED Phase 2

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

NCT03116698

COMPLETED Phase 3

DFN-11 Injection in Episodic Migraine With or Without Aura

NCT02569853

COMPLETED Phase 2

Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine

NCT02571049

COMPLETED Phase 3

A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies

NCT02572986

TERMINATED Phase 2

Pilot Study of DFN-11 Injection in Medication Overuse Headache

NCT02583425

COMPLETED Phase 1

Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults

NCT03051685

COMPLETED Phase 2

Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches

NCT02472418

COMPLETED Phase 3

DFN-02 Open Label Safety Study in Patients With Acute Migraine

NCT02279082

COMPLETED Phase 2

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

NCT02173301

COMPLETED Phase 3

A Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

NCT02060903

COMPLETED Phase 3

Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation

NCT02062060

COMPLETED Phase 1

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

NCT02061813

COMPLETED Phase 1

Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion

NCT02062073

COMPLETED Phase 2

Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery

NCT01888367

COMPLETED Phase 2

A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation

NCT02010333

COMPLETED Phase 3

Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation

NCT01674530

COMPLETED Phase 1

DFA-02 in Patients Undergoing Colorectal Surgery

NCT01496352

COMPLETED Phase 1

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

NCT01518699

COMPLETED Phase 2

An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation

NCT01336647

COMPLETED Phase 1

Bioequivalence Study of Finasteride 5 mg Tablet Formulations Under Fasting Conditions

NCT01264289

COMPLETED Phase 1

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions

NCT01264302

COMPLETED Phase 1

Bioequivalence Study of Desloratadine and Pseudoephedrine Extended-release Tablets Under Fed Conditions

NCT01506791

COMPLETED Phase 1

Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fed Condition

NCT01506037

COMPLETED Phase 1

Bioequivalence Study for Desloratadine OD Tablets 5 mg Under Fasting Condition

NCT01506050

COMPLETED Phase 1

Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions

NCT01314352

COMPLETED Phase 1

Bioavailability Study of Dr. Reddy's Desloratadine Tablets, 5 mg Under Fasting Conditions.

NCT01314339

COMPLETED Phase 1

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions

NCT01372345

COMPLETED Phase 1

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions

NCT01161979

COMPLETED Phase 1

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions

NCT01161966

COMPLETED Phase 1

Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Non-Fasting Conditions

NCT01372358

COMPLETED Phase 1

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions

NCT01581879

COMPLETED Phase 1

Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions

NCT01581866

COMPLETED Phase 1

Bioavailability Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fasting Conditions.

NCT01131897

COMPLETED Phase 1

Bioequivalence Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fed Conditions

NCT01132352

COMPLETED Phase 1

Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fed Condition

NCT01131975

COMPLETED Phase 1

Bioequivalence Study of Lamotrigine 25 mg Chewable Tablets of Dr.Reddy's Under Fasting Condition

NCT01131949

COMPLETED Phase 1

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fasting Condition

NCT01513720

COMPLETED Phase 1

Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition

NCT01513681

COMPLETED Phase 1

Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fasting Conditions

NCT01131923

COMPLETED Phase 1

Bioequivalence Study of Isotretinoin Capsules 20 mg Under Fasting Condition

NCT01888341

COMPLETED Phase 1

Bioequivalency Study of Amlodipine Besylate Tablets, 10 mg of Dr. Reddy's Under Fed Conditions

NCT01131936

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 30
Phase 2 12
Phase 3 10

How the Dr. Reddy's Laboratories Limited early-phase archive is shaped

52 indexed studies, none listed as recruiting (0% open); 51 completed (98%).

Phase mix: 10 late (III/IV) vs 42 early (I/II) (early-phase heavy).

Top condition: Healthy (6 trials), 8 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Dr. Reddy's Laboratories Limited: archived-pipeline peers nationwide

Peers matched on 52 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Dr. Reddy's Laboratories Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0204060 0%5%10%15% Total trials Recruiting share Dr. Reddy's Laboratories LimitedAlbany Medical CollegeBurzynski Research InstitutePTC TherapeuticsSpectrum Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Dr. Reddy's Laboratories Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Dr. Reddy's Laboratories Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 52 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Dr. Reddy's Laboratories Limited page

52 registered trials is a research-attention snapshot, not an endorsement of Dr. Reddy's Laboratories Limited or any single study.

  • None of Dr. Reddy's Laboratories Limited's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Healthy is the condition Dr. Reddy's Laboratories Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Dr. Reddy's Laboratories Limited pipeline card: 52 registered trials from official public datasets.Report a data error.